Phylomics aspires to connect asymptomatic patients with a non-invasive blood-based cancer screening. By combining high-sensitivity technologies and an unprecedented application of modern data science, Phylomics will develop products that provide meaningful and actionable recommendations for patients.
Cancer is a cell subject to random mutations. Such mutations are driven by the principles of evolution, such as natural selection. The complexity of tumors requires techniques that recognize the heterogeneity within cancers of a common origin and across patients.
Phylomics unique ability to classify tumor specimens based upon the relatedness among clinical specimens allows us to uncover biologically meaningful comparisons that permit clinically relevant interpretations, such as cancer diagnosis and identifying of proteins (i.e., biomarkers) that uniquely characterize specimens or a group of specimens.
A Closer Look
Cells produce byproducts that appear in the systemic circulation. These byproducts or metabolites directly correlate with the genetic code of the cancer cells from which they are derived. By measuring these byproducts, Phylomics process extrapolates information necessary for providing an accurate, actionable diagnosis.
Us vs. The Other Guys
With greater accuracy, affordability, and a non-invasive methodology, Phylomics stands out among the competition